Ketamine and esketamine for treatment-resistant depression: A systematic review of published studies
Medical Science August 30, 2026 Julia Rogała, Kinga Polityńska, Dominika Ruszel et al.
Treatment-resistant depression occurs in roughly one-third of individuals diagnosed with depression.Ketamine and esketamine have appeared as innovative antidepressant treatments that target the glutamatergic system and deliver promising therapeutic options for patients unresponsive to conventional monoaminergic antidepressants.This review delivers a complete analysis of the mechanisms of...